CASE REPORT ON DOCETAXEL-INDUCED INTERSTITIAL LUNG DISEASE

  • Remya Antony Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
  • Shiva Krishna Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
  • Jini James Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
  • Akhilesh Kunoor Department of Pulmonary Medicine, Amrita Institute of Medical Sciences, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
  • Meenu Vijayan Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.

Abstract

 

 Docetaxel belongs to taxane family of antineoplastic agents that are indicated for the treatment of locally advanced or metastatic non-small-cell lung cancer. Docetaxel is associated with many adverse effects, and pulmonary reaction has an incidence of 41%. However, interstitial pulmonary disease is found to occur only in <1% of the population as per the post-marketing surveillance reports. Here, we report a case of docetaxel-induced interstitial lung disease (ILD). The patient information and details were collected using the hospital information system. The adverse drug reaction (ADR) of ILD occurred after 5 cycles of chemotherapy with docetaxel at a dose of 60 mg/m2 that is 80 mg IV. The causality of the event in our case was assessed using the Naranjo ADR probability scale which marked a score of 7 (probable). It is necessary that all physicians be aware of the reaction and to closely monitor clinicoradiological and functional status of the patients at regular intervals after administration of docetaxel.

Keywords: Docetaxel, Interstitial lung disease, Naranjo adverse drug reaction probability scale.

Author Biographies

Remya Antony, Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
Department of pharmacy practice and PharmD Intern
Shiva Krishna, Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
Department of pharmacy practice and PharmD 5th year
Jini James, Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
Department of pharmacy practice and PharmD Intern
Akhilesh Kunoor, Department of Pulmonary Medicine, Amrita Institute of Medical Sciences, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
Assistant Professor, Department of Pulmonary Medicine
Meenu Vijayan, Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
Assistant Professor, Department of Pharmacy Practice

References

1. Ragaa I. Tropical parasitic lung diseases. Int J Pharm Pharm Sci 2015;7(5):2-12.
2. Fauzee NJ, Dong Z, Wang YL. Taxanes: Promising anti-cancer drugs. Asian Pac J Cancer Prev 2011;12(4):837-51.
3. Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001;85(9):1247-50.
4. Bonde S, Nair S. Advances in liposomal drug delivery system: Fascinating types and potential applications. Int J Appl Pharm 2017;9(3):1-7.
5. De Souza Bandeira TF, Mozegui GB, De Mello Vianna CM, Araujo RL, Da Silva Rodrigues MP, Do Valle PM. Cost-effectiveness analysis of trastuzumab in the treatment of metastatic breast cancer. Int J Pharm Pharm Sci 2015;7(4):307-12.
6. Wang CJ, Chang HT, Chang CY. Docetaxel-related interstitial pneumonitis. Ther Clin Risk Manag 2015;11:1813-6.
7. Min BD, Kang HW, Kim WT, Kim YJ, Yun SJ, Lee SC, et al. Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. Korean J Urol 2012;53(5):371-4.
8. Storaas E, Holmaas G, Gravdal K, Børretzen A, Eikesdal HP. Lethal pneumonitis after docetaxel chemotherapy: Case report and review of the literature. Acta Oncol 2013;52(5):1034-8.
9. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002;94(3):847-53.
10. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006;129(4):1031-8.
11. Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 2012;32(3):1103-6.
Statistics
375 Views | 417 Downloads
Citatons
How to Cite
Antony, R., S. Krishna, J. James, A. Kunoor, and M. Vijayan. “CASE REPORT ON DOCETAXEL-INDUCED INTERSTITIAL LUNG DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 10, Sept. 2017, pp. 10-12, doi:10.22159/ajpcr.2017.v10i10.19043.
Section
Case Study(s)